Last reviewed · How we verify
Neurology Group of Bergen County, P.A. — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Guanfacine (sustained release) | Guanfacine (sustained release) | marketed | Alpha-2A adrenergic receptor agonist | Alpha-2A adrenergic receptor | Neurology / Psychiatry |
Therapeutic area mix
- Neurology / Psychiatry · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Children's Hospital Medical Center, Cincinnati · 1 shared drug class
- Research Foundation for Mental Hygiene, Inc. · 1 shared drug class
- Shire · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Neurology Group of Bergen County, P.A.:
- Neurology Group of Bergen County, P.A. pipeline updates — RSS
- Neurology Group of Bergen County, P.A. pipeline updates — Atom
- Neurology Group of Bergen County, P.A. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Neurology Group of Bergen County, P.A. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/neurology-group-of-bergen-county-p-a. Accessed 2026-05-18.